2-Fluoro-5-bromoanisole | CAS:103291-07-2

We serve 2-Fluoro-5-bromoanisole CAS:103291-07-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Fluoro-5-bromoanisole

Chemical Name:2-Fluoro-5-bromoanisole
CAS.NO:103291-07-2
Synonyms:2-Fluoro-5-bromoanisole
2-Fluoro-5-bromoanisole
5-bromo-2-fluoroanisole
5-Bromo-2-fluorophenyl methyl ether
4-Bromo-1-fluoro-2-methoxybenzene
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 205.8±20.0 °C at 760 mmHg
Molecular Formula C7H6BrFO
Molecular Weight 205.024
Flash Point 92.5±6.0 °C
Vapour Pressure 0.4±0.4 mmHg at 25°C
Index of Refraction 1.519
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2-Fluoro-5-bromoanisole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Bromo-1-fluoro-2-methoxybenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Bromo-1-fluoro-2-methoxybenzene Use and application,2-Fluoro-5-bromoanisole technical grade,usp/ep/jp grade.


Related News: The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”Dimethyl 2-(2-Methoxyphenoxy)Malonate manufacturer The government will also send a charter flight with an Air New Zealand crew to repatriate up to 300 citizens in Wuhan.7-chloro-1-heptanol acetate supplier In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining.2,5-Dichloro-4,6-dimethylnicotinonitrile vendor In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining.Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.